🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Dillon Corrigan

Cleveland Clinic

ORCID: 0000-0002-5390-0139

Also affiliated with Io Therapeutics (United States), Foghorn Therapeutics (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage”.

Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage

Histopathology(2024)10.1111/his.15231

N/A

0.524DataRank · unranked

32 citations

Lara R. Harik, Eric A. Klein, Jianbo Li, Dillon Corrigan, Shiguang Liu +18 more

AI-generated R.E.N.A.L.+ Score Surpasses Human-generated Score in Predicting Renal Oncologic Outcomes

Urology(2023)10.1016/j.urology.2023.07.017

N/A

0.373DataRank · unranked

11 citations

Andrew Wood, Tarik Benidir, Nicholas Heller, Fabian Isensee, Resha Tejpaul +16 more

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3790

N/A

0DataRank · unranked

11 citations

Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás‐Cardama, Sarah A. Reilly +25 more